Literature DB >> 33973922

The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.

Alex K Gertner1, Jason S Rotter, Margaret E Holly, Christopher M Shea, Sherri L Green, Marisa Elena Domino.   

Abstract

OBJECTIVE: To determine if individuals newly diagnosed with opioid use disorder (OUD) who saw a primary care provider (PCP) before or on the date of diagnosis had higher rates of medication treatment for OUD (MOUD).
METHODS: Observational study using logistic regression with claims data from Medicaid and a large private insurer in North Carolina from January 2014 to July 2017. KEY
RESULTS: Between 2014 and 2017, the prevalence of diagnosed OUD increased by 47% among Medicaid enrollees and by 76% among the privately insured. Over the same time period, the percent of people with an OUD who received MOUD fell among both groups, while PCP involvement in treatment increased. Of Medicaid enrollees receiving buprenorphine, the percent receiving buprenorphine from a PCP increased from 32% in 2014 to 39% in 2017. Approximately 82% of people newly diagnosed with OUD had a PCP visit in the 12 months before diagnosis in Medicaid and private insurance. Those with a prior PCP visit were not more likely to receive MOUD. Seeing a PCP at diagnosis was associated with a higher probability of receiving MOUD than seeing an emergency provider but a lower probability than seeing a behavioral health specialist or other provider type.
CONCLUSIONS: People newly diagnosed with OUD had high rates of contact with PCPs before diagnosis, supporting the importance of PCPs in diagnosing OUD and connecting people to MOUD. Policies and programs to increase access to MOUD and improve PCPs' ability to connect people to evidence-based treatment are needed.
Copyright © 2021 American Society of Addiction Medicine.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33973922      PMCID: PMC8578588          DOI: 10.1097/ADM.0000000000000860

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  22 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  Co-occurring substance use and mental disorders among adults with opioid use disorder.

Authors:  Christopher M Jones; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2019-02-14       Impact factor: 4.492

3.  Primary Care and the Opioid-Overdose Crisis - Buprenorphine Myths and Realities.

Authors:  Sarah E Wakeman; Michael L Barnett
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

5.  The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.

Authors:  Evan S Cole; Ellen DiDomenico; Gerald Cochran; Adam J Gordon; Walid F Gellad; Janice Pringle; Jack Warwick; Chung-Chou H Chang; Joo Yeon Kim; Julie Kmiec; David Kelley; Julie M Donohue
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

6.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

7.  Providing Office-Based Treatment of Opioid Use Disorder.

Authors:  Courtenay Gilmore Wilson; E Blake Fagan
Journal:  Ann Fam Med       Date:  2017-09       Impact factor: 5.166

8.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

9.  Access to Addiction Pharmacotherapy in Private Health Plans.

Authors:  Sharon Reif; Constance M Horgan; Dominic Hodgkin; Ann-Marie Matteucci; Timothy B Creedon; Maureen T Stewart
Journal:  J Subst Abuse Treat       Date:  2016-03-14

10.  Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders.

Authors:  Miriam Komaromy; Dan Duhigg; Adam Metcalf; Cristina Carlson; Summers Kalishman; Leslie Hayes; Tom Burke; Karla Thornton; Sanjeev Arora
Journal:  Subst Abus       Date:  2016       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.